8-KMaterial AgreementsOther EventsExhibits & Filings

ABBOTT LABORATORIES 8-K Report, Material Agreement (Apr 28, 2016)

Filed April 28, 2016For Securities:ABT

Summary

Abbott Laboratories (ABT) has announced a significant strategic move with the signing of an Agreement and Plan of Merger with St. Jude Medical, Inc. This transaction, filed on April 28, 2016, involves a merger whereby St. Jude Medical will be acquired by Abbott. The deal is structured as a "merger of equals" with a "buy-in" component for Abbott. Shareholders of St. Jude Medical will receive a combination of cash and Abbott common stock. Specifically, each St. Jude share will be converted into $46.75 in cash and 0.8708 shares of Abbott common stock, subject to standard closing conditions and potential adjustments. This acquisition signals Abbott's intent to expand its presence and capabilities, likely within the medical device sector where St. Jude Medical is a prominent player.

Key Highlights

  • 1Abbott Laboratories entered into a Merger Agreement with St. Jude Medical, Inc. on April 27, 2016.
  • 2The transaction involves Abbott acquiring St. Jude Medical through a two-step merger process.
  • 3St. Jude Medical shareholders will receive $46.75 in cash and 0.8708 shares of Abbott common stock per St. Jude share.
  • 4Completion of the merger is subject to customary closing conditions, including shareholder approval, regulatory approvals (like HSR), and SEC filings.
  • 5Abbott has secured a commitment for up to $17.2 billion in senior unsecured bridge loans to finance the transaction.
  • 6A joint press release was issued on April 28, 2016, announcing the merger, and an investor conference call was scheduled for the same day.
  • 7The filing includes references to important additional information to be filed with the SEC, including a Form S-4 registration statement and a proxy statement/prospectus.

Frequently Asked Questions

This 8-K filing announces Abbott Laboratories' entry into a material definitive agreement for the acquisition of St. Jude Medical, Inc. It details the terms of the merger, the consideration to be paid to St. Jude shareholders, and the conditions required for the transaction to close.

While the exact total value is not explicitly stated as a single number in this filing, the transaction involves St. Jude Medical shareholders receiving $46.75 in cash and 0.8708 shares of Abbott common stock per St. Jude share. Abbott has also secured $17.2 billion in committed bridge loans, indicating a substantial financial undertaking.

Key conditions include the adoption of the Merger Agreement by St. Jude shareholders, approval for listing Abbott shares on the NYSE, no laws or orders prohibiting the merger, effectiveness of the SEC registration statement for Abbott shares, expiration of the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act, and receipt of other specified antitrust approvals. Both parties' representations and warranties must be true, obligations performed, and no material adverse effect must occur.

While this 8-K focuses on the agreement details, the acquisition of St. Jude Medical, a leader in cardiovascular and other medical technologies, is expected to significantly expand Abbott's presence in the cardiovascular device market and broaden its portfolio, likely leading to synergies and enhanced growth opportunities in the medical device sector.